Davita Inc. Stock
Davita Inc. Stock
A loss of -3.000% shows a downward development for Davita Inc..
The community is currently still undecided about Davita Inc. with 1 Buy predictions and 1 Sell predictions.
With a target price of 119 € there is a slightly negative potential of -3.21% for Davita Inc. compared to the current price of 122.95 €.
Our community identified positive and negative aspects for Davita Inc. stock for the coming years. 0 users see the criterium "Worthwhile Investment for the next years" as a plus for the Davita Inc. stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.
Pros and Cons of Davita Inc. in the next few years
Pros
?
S********** s********
?
M***** P*******
?
G***** c******* t* c**********
Cons
?
B****
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Davita Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Davita Inc. | -3.000% | -1.858% | -4.556% | -4.592% | 31.429% | 65.947% | 40.241% |
| Chemed Corp. | -0.630% | -2.395% | -5.780% | -37.905% | -10.440% | - | - |
| Select Medical Holdings | 0.740% | 0.000% | 0.000% | -4.167% | 10.400% | -45.238% | -52.740% |
| Teladoc Health Inc | 5.100% | -3.157% | -5.301% | -30.293% | -24.674% | -80.877% | -97.169% |
Comments
DaVita (NYSE:DVA) had its "buy" rating reaffirmed by analysts at UBS Group AG.
Show more
Ratings data for DVA provided by MarketBeat
DaVita (NYSE:DVA) had its price target lowered by analysts at Bank of America Corporation from $145.00 to $140.00. They now have an "underperform" rating on the stock.
Show more
Ratings data for DVA provided by MarketBeat
DaVita Inc. (NYSE: DVA) had its price target raised by analysts at UBS Group AG from $169.00 to $175.00. They now have a "buy" rating on the stock.
Show more
Ratings data for DVA provided by MarketBeat